nach oben

Cancer and Metastasis Reviews

Erschienen in:

06.08.2022

Clinical interventions to break the obesity and cancer link: a narrative review

verfasst von: Nakul J. Bhardwaj, Kacey Chae, Jennifer Y. Sheng, Hsin-Chieh Yeh

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Excess body weight is a significant risk factor for the development and recurrence of many types of cancer. Patients with a history or current diagnosis of cancer who are overweight or have obesity have an increased risk of cancer treatment-related morbidity, recurrence, and decreased quality of life. Weight loss and maintenance of a healthy body weight may reduce cancer morbidity and recurrence in cancer survivors. While guidelines for cancer survivorship elaborate sufficiently on lifestyle interventions, little guidance is provided when considering additional therapies like anti-obesity pharmacotherapy or bariatric surgery for weight loss. This review will highlight and address current recommendations and feasible interventions that clinicians may consider to further reduce the incidence and recurrence of cancer in patients with obesity.

Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016). Trends in obesity among adults in the United States, 2005 to 2014. JAMA - Journal of the American Medical Association, 315(21), 2284–91. https://doi.org/10.1001/jama.2016.6458

Schmidt, C. (2018). The fight against non-communicable disease in emerging economies. Nature, 562(7727), S65–S67. https://doi.org/10.1038/d41586-018-06974-1

Habib, S. H., & Saha, S. (2010). Burden of non-communicable disease: Global overview. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 4(1), 41–47. https://doi.org/10.1016/j.dsx.2008.04.005

Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016). Body Fatness and Cancer — Viewpoint of the IARC Working Group. New England Journal of Medicine, 375(8), 794–8. https://doi.org/10.1056/nejmsr1606602

Malik, P. R. A., Doumouras, A. G., Malhan, R. S., Lee, Y., Boudreau, V., Barlow, K., Karpinski, M., & Anvari, M. (2021). Obesity, cancer, and risk reduction with bariatric surgery. Surgical Clinics of North America, 101(2), 239–254. https://doi.org/10.1016/j.suc.2020.12.003

Bianchini, F., Kaaks, R., & Vainio, H. (2002). Overweight, obesity, and cancer risk. Lancet Oncology, 3(9), 565–74. https://doi.org/10.1016/S1470-2045(02)00849-5

Furer, A., Afek, A., Sommer, A., Keinan-Boker, L., Derazne, E., Levi, Z., Tzur, D., Tiosano, S., Shina, A., Glick, Y., Kark, J. D., Tirosh, A., & Twig, G. (2020). Adolescent obesity and midlife cancer risk: a population-based cohort study of 2·3 million adolescents in Israel. The Lancet Diabetes and Endocrinology, 8(3), 216–225. https://doi.org/10.1016/S2213-8587(20)30019-X

Biganzoli, E., Desmedt, C., Fornili, M., de Azambuja, E., Cornez, N., Ries, F., Closon-Dejardin, M. T., Kerger, J., Focan, C., di Leo, A., Nogaret, J. M., Sotiriou, C., Piccart, M., & Demicheli, R. (2017). Recurrence dynamics of breast cancer according to baseline body mass index. European Journal of Cancer, 87, 10–20. https://doi.org/10.1016/j.ejca.2017.10.007

Trentham-Dietz, A., Newcomb, P. A., Nichols, H. B., & Hampton, J. M. (2007). Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Research and Treatment, 105(2), 195–207. https://doi.org/10.1007/s10549-006-9446-y

10.

Harvey, A. E., Lashinger, L. M., & Hursting, S. D. (2011). The growing challenge of obesity and cancer: An inflammatory issue. Annals of the New York Academy of Sciences, 1229(1), 45–52. https://doi.org/10.1111/j.1749-6632.2011.06096.x

11.

Calle, E. E., & Kaaks, R. (2004). Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Reviews Cancer, 4(8), 579–91. https://doi.org/10.1038/nrc1408

12.

Brauna, S., Bitton-Worms, K., & le Roith, D. (2011). The link between the metabolic syndrome and cancer. International Journal of Biological Sciences, 7(7), 1003–15. https://doi.org/10.7150/ijbs.7.1003

13.

Berger, N. A. (2014). Obesity and cancer pathogenesis. Annals of the New York Academy of Sciences, 1311(1), 57–76. https://doi.org/10.1111/nyas.12416

14.

Nock, N. L., & Berger, N. A. (2010). Obesity and Cancer: Overview of Mechanisms. In N. A. Berger (Ed), Cancer and Energy Balance, Epidemiology and Overview (pp. 129–79). New York: Springer. https://doi.org/10.1007/978-1-4419-5515-9_5

15.

Hursting, S. D., & Berger, N. A. (2010). Energy balance, host-related factors, and cancer progression. Journal of Clinical Oncology, 28(26), 4058–65. https://doi.org/10.1200/JCO.2010.27.9935

16.

Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Uriell-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 431(7007), 461–6. https://doi.org/10.1038/nature02924

17.

Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004). IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3), 285–96. https://doi.org/10.1016/j.cell.2004.07.013

18.

Bickenbach, K. A., Denton, B., Gonen, M., Brennan, M. F., Coit, D. G., & Strong, V. E. (2013). Impact of obesity on perioperative complications and long-term survival of patients with gastric cancer. Annals of Surgical Oncology, 20(3), 780–7. https://doi.org/10.1245/s10434-012-2653-3

19.

Wu, X. S., Wu, W. G., Li, M. L., Yang, J. H., Ding, Q. C., Zhang, L., Mu, J. S., Gu, J., Dong, P., Lu, J. H., & Liu, Y. bin. (2013). Impact of being overweight on the surgical outcomes of patients with gastric cancer: A meta-analysis. World Journal of Gastroenterology, 19(28), 4596–606. https://doi.org/10.3748/wjg.v19.i27.4596

20.

Santoso, J. T., Barton, G., Riedley-Malone, S., & Wan, J. Y. (2012). Obesity and perioperative outcomes in endometrial cancer surgery. Archives of Gynecology and Obstetrics, 285(4), 1139–44. https://doi.org/10.1007/s00404-011-2116-2

21.

Harrison, R., Iniesta, M. D., Pitcher, B., Ramirez, P. T., Cain, K., Siverand, A. M., Mena, G., Lasala, J., & Meyer, L. A. (2020). Enhanced recovery for obese patients undergoing gynecologic cancer surgery. International Journal of Gynecological Cancer, 30(10), 1595–1602. https://doi.org/10.1136/ijgc-2020-001663

22.

Hussan, H., Gray, D. M., Hinton, A., Krishna, S. G., Conwell, D. L., & Stanich, P. P. (2016). Morbid Obesity is Associated with Increased Mortality, Surgical Complications, and Incremental Health Care Utilization in the Peri-Operative Period of Colorectal Cancer Surgery. World Journal of Surgery, 40(4), 987–94. https://doi.org/10.1007/s00268-015-3358-0

23.

Mustafa Ali, M., Moeller, M., Rybicki, L., & Moore, H. C. F. (2017). Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Research and Treatment, 166(2), 519–526. https://doi.org/10.1007/s10549-017-4437-8

24.

Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016). Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Research and Treatment, 159(2), 327–333. https://doi.org/10.1007/s10549-016-3939-0

25.

Guenancia, C., Lefebvre, A., Cardinale, D., Yu, A. F., Ladoire, S., Ghiringhelli, F., Zeller, M., Rochette, L., Cottin, Y., & Vergely, C. (2016). Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis. Journal of Clinical Oncology, 34(26), 3157–65. https://doi.org/10.1200/JCO.2016.67.4846

26.

Gunaldi, M., Duman, B. B., Afsar, C. U., Paydas, S., Erkisi, M., Kara, I. O., & Sahin, B. (2016). Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. Journal of Oncology Pharmacy Practice, 22(2), 242–7. https://doi.org/10.1177/1078155214567162

27.

Wang, H. Y., Yin, B. B., Jia, D. Y., & Hou, Y. L. (2017). Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer. Oncotarget, 8(45), 79289–79297. https://doi.org/10.18632/oncotarget.17808

28.

Schmidt, M. E., Wiskemann, J., Schneeweiss, A., Potthoff, K., Ulrich, C. M., & Steindorf, K. (2018). Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. International Journal of Cancer, 142(6), 1148–1157. https://doi.org/10.1002/ijc.31138

29.

Ahmed, R. L., Schmitz, K. H., Prizment, A. E., & Folsom, A. R. (2011). Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Research and Treatment, 130(3), 981–91. https://doi.org/10.1007/s10549-011-1667-z

30.

Meeske, K. A., Sullivan-Halley, J., Smith, A. W., McTiernan, A., Baumgartner, K. B., Harlan, L. C., & Bernstein, L. (2009). Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Research and Treatment, 113(2), 383–91. https://doi.org/10.1007/s10549-008-9940-5

31.

Ridner, S. H., Dietrich, M. S., Stewart, B. R., & Armer, J. M. (2011). Body mass index and breast cancer treatment-related lymphedema. Supportive Care in Cancer, 19(6), 853–7. https://doi.org/10.1007/s00520-011-1089-9

32.

Pack, Q. R., Rodriguez-Escudero, J. P., Thomas, R. J., Ades, P. A., West, C. P., Somers, V. K., & Lopez-Jimenez, F. (2014). The prognostic importance of weight loss in coronary artery disease: A systematic review and meta-analysis. Mayo Clinic Proceedings, 89(10), 1368–77. https://doi.org/10.1016/j.mayocp.2014.04.033

33.

Kritchevsky, S. B., Beavers, K. M., Miller, M. E., Shea, M. K., Houston, D. K., Kitzman, D. W., & Nicklas, B. J. (2015). Intentional weight loss and all-cause mortality: A meta-analysis of randomized clinical trials. PLoS ONE, 10(3), e0121993. https://doi.org/10.1371/journal.pone.0121993

34.

Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011). Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. New England Journal of Medicine, 364(13), 1218–29. https://doi.org/10.1056/nejmoa1008234

35.

Yeh, H. C., Bantle, J. P., Cassidy-Begay, M., Blackburn, G., Bray, G. A., Byers, T., Clark, J. M., Coday, M., Egan, C., Espeland, M. A., Foreyt, J. P., Garcia, K., Goldman, V., Gregg, E. W., Hazuda, H. P., Hesson, L., Hill, J. O., Horton, E. S., Jakicic, J. M., … Yanovski, S. Z. (2020). Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 28(9), 1678–1686. https://doi.org/10.1002/oby.22936

36.

Fabian, C. J., Kimler, B. F., Donnelly, J. E., Sullivan, D. K., Klemp, J. R., Petroff, B. K., Phillips, T. A., Metheny, T., Aversman, S., Yeh, H. W., Zalles, C. M., Mills, G. B., & Hursting, S. D. (2013). Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. Breast Cancer Research and Treatment, 142(1), 119–32. https://doi.org/10.1007/s10549-013-2730-8

37.

Sparano, J. A., Wang, M., Zhao, F., Stearns, V., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., Fetting, J., & Davidson, N. E. (2012). Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer, 118(23), 5937–46. https://doi.org/10.1002/cncr.27527

38.

Eliassen, A. H., Colditz, G. A., Rosner, B., Willett, W. C., & Hankinson, S. E. (2006). Adult weight change and risk of postmenopausal breast cancer. Journal of the American Medical Association, 296(2), 193–201. https://doi.org/10.1001/jama.296.2.193

39.

Demark-Wahnefried, W., Platz, E. A., Ligibel, J. A., Blair, C. K., Courneya, K. S., Meyerhardt, J. A., Ganz, P. A., Rock, C. L., Schmitz, K. H., Wadden, T., Philip, E. J., Wolfe, B., Gapstur, S. M., Ballard-Barbash, R., McTiernan, A., Minasian, L., Nebeling, L., & Goodwin, P. J. (2012). The role of obesity in cancer survival and recurrence. Cancer Epidemiology Biomarkers and Prevention, 21(8), 1244–59. https://doi.org/10.1158/1055-9965.EPI-12-0485

40.

Michaud, T. L., You, W., Wilson, K. E., Su, D., McGuire, T. J., Almeida, F. A., Bayer, A. L., & Estabrooks, P. A. (2017). Cost effectiveness and return on investment of a scalable community weight loss intervention. Preventive Medicine, 105, 295–303. https://doi.org/10.1016/j.ypmed.2017.10.011

41.

Teras, L. R., Patel, A. v., Wang, M., Yaun, S. S., Anderson, K., Brathwaite, R., Caan, B. J., Chen, Y., Connor, A. E., Eliassen, A. H., Gapstur, S. M., Gaudet, M. M., Genkinger, J. M., Giles, G. G., Lee, I. M., Milne, R. L., Robien, K., Sawada, N., Sesso, H. D., … Smith-Warner, S. A. (2020). Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data. Journal of the National Cancer Institute, 112(9), 929–937. https://doi.org/10.1093/jnci/djz226

42.

Denlinger, C. S., Sanft, T., Moslehi, J. J., Overholser, L., Armenian, S., Baker, K. S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., Goldman, M., Henry, N. L., Hill-Kayser, C., Hudson, M., Khakpour, N., Koura, D., McDonough, A. L., Melisko, M., Mooney, K., Moore, H. C. F., & Freedman-Cass, D. A. (2020). NCCN Guidelines Insights: Survivorship, Version 2.2020. Journal of the National Comprehensive Cancer Network, 18(8), 1016–1023. https://doi.org/10.6004/jnccn.2020.0037

43.

Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., Loria, C. M., Millen, B. E., Nonas, C. A., Pi-Sunyer, F. X., Stevens, J., Stevens, V. J., Wadden, T. A., Wolfe, B. M., & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Journal of the American College of Cardiology, 63(25), 2985–3023. https://doi.org/10.1016/j.jacc.2013.11.004

44.

Segal, R., Pond, G. R., Vallis, M., Dion, M., Pritchard, K. I., Ligibel, J. A., Levine, M. N., & Goodwin, P. J. (2011). Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. Journal of Clinical Oncology, 29(15_suppl). https://doi.org/10.1200/jco.2011.29.15_suppl.512

45.

Thomson, C. A., Stopeck, A. T., Bea, J. W., Cussler, E., Nardi, E., Frey, G., & Thompson, P. A. (2010). Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutrition and Cancer, 62(8), 1142–52. https://doi.org/10.1080/01635581.2010.513803

46.

Mefferd, K., Nichols, J. F., Pakiz, B., & Rock, C. L. (2007). A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors. Breast Cancer Research and Treatment, 104(2), 145–52. https://doi.org/10.1007/s10549-006-9410-x

47.

Group, D. P. P. R. (2002). Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin - NEJMoa012512. New England Journal of Medicine, 346(6), 393–403. https://doi.org/10.1056/NEJMoa012512

48.

Goldstein, D. J. (1992). Beneficial health effects of modest weight loss. International Journal of Obesity and Related Metabolic Disorders, 16(6), 397–415.

49.

Rock, C. L., Thomson, C., Gansler, T., et al. (2020). American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians, 70(4), 245–271.

50.

Rock, C. L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., Bandera, E. v., Hamilton, K. K., Grant, B., McCullough, M., Byers, T., & Gansler, T. (2012). Nutrition and physical activity guidelines for cancer survivors. CA: A Cancer Journal for Clinicians, 62(4), 243–74. https://doi.org/10.3322/caac.21142

51.

van Blarigan, E. L., Fuchs, C. S., Niedzwiecki, D., Zhang, S., Saltz, L. B., Mayer, R. J., Mowat, R. B., Whittom, R., Hantel, A., Benson, A., Atienza, D., Messino, M., Kindler, H., Venook, A., Ogino, S., Giovannucci, E. L., Ng, K., & Meyerhardt, J. A. (2018). Association of survival with adherence to the American cancer society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncology, 4(6), 783–790. https://doi.org/10.1001/jamaoncol.2018.0126

52.

Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., Hurria, A., Marks, L. B., LaMonte, S. J., Warner, E., Lyman, G. H., & Ganz, P. A. (2016). American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA: A Cancer Journal for Clinicians, 66(1), 43–73. https://doi.org/10.3322/caac.21319

53.

Sanft, T., Denlinger, C. S., Armenian, S., Baker, K. S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., Goldman, M., Hudson, M., Khakpour, N., Koura, D., Lally, R. M., Langbaum, T. S., McDonough, A. L., Melisko, M., Mooney, K., Moore, H. C. F., Moslehi, J. J., O’Connor, T., & Freedman-Cass, D. A. (2019). NCCN Guidelines Insights: Survivorship, Version 2.2019. Journal of the National Comprehensive Cancer Network, 17(7), 784–794. https://doi.org/10.6004/jnccn.2019.0034

54.

Bruno, E., Gargano, G., Villarini, A., Traina, A., Johansson, H., Mano, M. P., Santucci De Magistris, M., Simeoni, M., Consolaro, E., Mercandino, A., Barbero, M., Galasso, R., Bassi, M. C., Zarcone, M., Zagallo, E., Venturelli, E., Bellegotti, M., Berrino, F., & Pasanisi, P. (2016). Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients. International Journal of Cancer, 138(1), 237–44. https://doi.org/10.1002/ijc.29689

55.

The World Cancer Research Fund (WCRF. (2018). World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Continuous Update Project Expert Report 2018. Continuous Update Project Expert Report 2018.

56.

Engin, A. (2017). The definition and prevalence of obesity and metabolic syndrome. Advances in Experimental Medicine and Biology, 960, 1–17. https://doi.org/10.1007/978-3-319-48382-5_1

57.

George, S. M., Ballard-Barbash, R., Shikany, J. M., Caan, B. J., Freudenheim, J. L., Kroenke, C. H., Vitolins, M. Z., Beresford, S. A., & Neuhouser, M. L. (2014). Better postdiagnosis diet quality is associated with reduced risk of death among postmenopausal women with invasive breast cancer in the women’s health initiative. Cancer Epidemiology Biomarkers and Prevention, 23(4), 575–83. https://doi.org/10.1158/1055-9965.EPI-13-1162

58.

Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., Hudis, C., Butler, J., Merkel, D., Kristal, A., Caan, B., Michaelson, R., Vinciguerra, V., del Prete, S., Winkler, M., & Elashoff, R. M. (2006). Dietary fat reduction and breast cancer outcome: Interim efficacy results from the women’s intervention nutrition study. Journal of the National Cancer Institute, 98(24), 1767–76. https://doi.org/10.1093/jnci/djj494

59.

Pierce, J. P., Natarajan, L., Caan, B. J., Parker, B. A., Greenberg, E. R., Flatt, S. W., Rock, C. L., Kealey, S., Al-Delaimy, W. K., Bardwell, W. A., Carlson, R. W., Emond, J. A., Faerber, S., Gold, E. B., Hajek, R. A., Hollenbach, K., Jones, L. A., Karanja, N., Madlensky, L., & Stefanick, M. L. (2007). Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: The Women’s Healthy Eating and Living (WHEL) randomized trial. Journal of the American Medical Association, 298(3), 289–98. https://doi.org/10.1001/jama.298.3.289

60.

Stearns, V. (2008). A diet low in fat and high in vegetables, fruit, and fiber following breast cancer treatment did not reduce new breast cancer events. ACP Journal Club, 148(1), 8. https://doi.org/10.7326/acpjc-2008-148-1-008

61.

Hall, K. D., Heymsfield, S. B., Kemnitz, J. W., Klein, S., Schoeller, D. A., & Speakman, J. R. (2012). Energy balance and its components: Implications for body weight regulation. American Journal of Clinical Nutrition, 95(4), 989–94. https://doi.org/10.3945/ajcn.112.036350

62.

Hall, K. D., & Chow, C. C. (2013). Why is the 3500 kcal per pound weight loss rule wrong? International Journal of Obesity, 37(12):1614. https://doi.org/10.1038/ijo.2013.112

63.

Thomas, D. M., Martin, C. K., Lettieri, S., Bredlau, C., Kaiser, K., Church, T., Bouchard, C., & Heymsfield, S. B. (2013). Can a weight loss of one pound a week be achieved with a 3500-kcal deficit? Commentary on a commonly accepted rule. International Journal of Obesity, 37(12), 1611–3. https://doi.org/10.1038/ijo.2013.51

64.

Sheng, J. Y., Sharma, D., Jerome, G., & Santa-Maria, C. A. (2018). Obese breast cancer patients and survivors: Management considerations. Oncology (Williston Park), 32(8):410–7.

65.

Wadden, T. A., Butryn, M. L., Hong, P. S., & Tsai, A. G. (2014). Behavioral treatment of obesity in patients encountered in primary care settings: A systematic review. JAMA - Journal of the American Medical Association, 312(17), 1779–91. https://doi.org/10.1001/jama.2014.14173

66.

Appel, L. J., Clark, J. M., Yeh, H.-C., Wang, N.-Y., Coughlin, J. W., Daumit, G., Miller, E. R., Dalcin, A., Jerome, G. J., Geller, S., Noronha, G., Pozefsky, T., Charleston, J., Reynolds, J. B., Durkin, N., Rubin, R. R., Louis, T. A., & Brancati, F. L. (2011). Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice. New England Journal of Medicine, 365(21), 1959–68. https://doi.org/10.1056/nejmoa1108660

67.

Mutrie, N., Campbell, A. M., Whyte, F., McConnachie, A., Emslie, C., Lee, L., Kearney, N., Walker, A., & Ritchie, D. (2007). Benefits of supervised group exercise programme for women being treated for early stage breast cancer: Pragmatic randomised controlled trial. British Medical Journal, 334(7592), 517. https://doi.org/10.1136/bmj.39094.648553.AE

68.

Villarini, A., Pasanisi, P., Raimondi, M., Gargano, G., Bruno, E., Morelli, D., Evangelista, A., Curtosi, P., & Berrino, F. (2012). Preventing weight gain during adjuvant chemotherapy for breast cancer: A dietary intervention study. Breast Cancer Research and Treatment, 135(2), 581–9. https://doi.org/10.1007/s10549-012-2184-4

69.

van Waart, H., van Harten, W. H., Buffart, L. M., Sonke, G. S., Stuiver, M. M., & Aaronson, N. K. (2016). Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer? Psycho-Oncology, 25(8), 964–970. https://doi.org/10.1002/pon.3936

70.

Laudenslager, M., Chaudhry, Z. W., Rajagopal, S., Clynes, S., & Gudzune, K. A. (2021). Commercial Weight Loss Programs in the Management of Obesity: an Update. Current Obesity Reports. 10(2), 90–99. https://doi.org/10.1007/s13679-021-00428-y

71.

Brauer, P., Connor Gorber, S., Shaw, E., Singh, H., Bell, N., Shane, A. R. E., Jaramillo, A., & Tonelli, M. (2015). Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ, 187(3), 184–195. https://doi.org/10.1503/cmaj.140887

72.

Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013). Safety of antiobesity drugs. Therapeutic Advances in Drug Safety, 4(4), 171–81. https://doi.org/10.1177/2042098613489721

73.

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 100(2), 342–62. https://doi.org/10.1210/jc.2014-3415

74.

Mauer, Y., Parker, M., & Kashyap, S. R. (2021). Antiobesity drug therapy: An individualized and comprehensive approach. Cleveland Clinic Journal of Medicine, 88(8), 440–448. https://doi.org/10.3949/ccjm.88a.20080

75.

Saunders, K. H., Shukla, A. P., Igel, L. I., & Aronne, L. J. (2017). Obesity: When to consider medication. Journal of Family Practice, 66(10), 608–616.

76.

Kanj, A., & Levine, D. (2020). Overcoming obesity: Weight-loss drugs are underused. Cleveland Clinic Journal of Medicine, 87(10), 602–604. https://doi.org/10.3949/CCJM.87A.19102

77.

Suissa, K., Schneeweiss, S., Kim, D. W., & Patorno, E. (2021). Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes, Obesity and Metabolism, 23(7), 1542–1551. https://doi.org/10.1111/dom.14367

78.

American Society of Clinical Oncology. (2014). Obesity and Cancer: A Guide for Oncology Providers.

79.

Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016). American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22, 1–203. https://doi.org/10.4158/EP161365.GL

80.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism: Clinical and Experimental, 92, 170–192. https://doi.org/10.1016/j.metabol.2018.10.010

81.

Pantalone, K. M., Smolarz, B. G., Ramasamy, A., Baz Hecht, M., Harty, B. J., Rogen, B., Griebeler, M. L., Borukh, E., Young, J. B., & Burguera, B. (2021). Effectiveness of Combining Antiobesity Medication with an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial. JAMA Network Open, 4(7):e2116595. https://doi.org/10.1001/jamanetworkopen.2021.16595

82.

Schcolnik-Cabrera, A., Chávez-Blanco, A., Domínguez-Gómez, G., Taja-Chayeb, L., Morales-Barcenas, R., Trejo-Becerril, C., Perez-Cardenas, E., Gonzalez-Fierro, A., & Dueñas-González, A. (2018). Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opinion on Investigational Drugs, 27(5), 475–489. https://doi.org/10.1080/13543784.2018.1471132

83.

Kant, S., Kumar, A., & Singh, S. M. (2012). Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: Role of cell survival regulatory molecules. Biochimica et Biophysica Acta - General Subjects, 1820(11), 1764–73. https://doi.org/10.1016/j.bbagen.2012.07.010

84.

Menendez, J. A., Vellon, L., & Lupu, R. (2006). The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin^TM) in chemoresistant ovarian cancer cells. International Journal of Gynecological Cancer, 16(1), 219–21. https://doi.org/10.1111/j.1525-1438.2006.00297.x

85.

Peng, H., Wang, Q., Qi, X., Wang, X., & Zhao, X. (2018). Orlistat induces apoptosis and protective autophagy in ovarian cancer cells: involvement of Akt-mTOR-mediated signaling pathway. Archives of Gynecology and Obstetrics, 298(3), 597–605. https://doi.org/10.1007/s00404-018-4841-2

86.

Jin, B. R., Kim, H. J., Sim, S. A., Lee, M., & An, H. J. (2021). Anti‐obesity drug orlistat alleviates western‐diet‐driven colitis‐associated colon cancer via inhibition of stat3 and nf‐κb‐mediated signaling. Cells, 10(8), 2060. https://doi.org/10.3390/cells10082060

87.

Gnesin, F., Thuesen, A. C. B., Kähler, L. K. A., Madsbad, S., & Hemmingsen, B. (2020). Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 6(6):CD012906. https://doi.org/10.1002/14651858.CD012906.pub2

88.

Yerevanian, A., & Soukas, A. A. (2019). Metformin: Mechanisms in Human Obesity and Weight Loss. Current Obesity Reports, 8(2), 156–164. https://doi.org/10.1007/s13679-019-00335-3

89.

Shi, W. Y., Xiao, D., Wang, L., Dong, L. H., Yan, Z. X., Shen, Z. X., Chen, S. J., Chen, Y., & Zhao, W. L. (2012). Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death and Disease, 3(3), e275. https://doi.org/10.1038/cddis.2012.13

90.

Podhorecka, M. (2021). Metformin - its anti-cancer effects in hematologic malignancies. Oncology Reviews, 15(1), 514. https://doi.org/10.4081/oncol.2021.514

91.

Sahra, I. ben, Regazzetti, C., Robert, G., Laurent, K., le Marchand-Brustel, Y., Auberger, P., Tanti, J. F., Giorgetti-Peraldi, S., & Bost, F. (2011). Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Research, 71(13), 4366–72. https://doi.org/10.1158/0008-5472.CAN-10-1769

92.

Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C. N., Zhang, J., & Lu, Y. (2017). Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 36(1), 1–9. https://doi.org/10.1186/s40880-017-0184-9

93.

Niraula, S., Dowling, R. J. O., Ennis, M., Chang, M. C., Done, S. J., Hood, N., Escallon, J., Leong, W. L., McCready, D. R., Reedijk, M., Stambolic, V., & Goodwin, P. J. (2012). Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study, 135(3), 821–30. https://doi.org/10.1007/s10549-012-2223-1

94.

Goodwin, P., Pritchard, K., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008). Insulin-lowering effects of metformin in women with early breast cancer. Clinical Breast Cancer, 8(6), 501–5. https://doi.org/10.3816/CBC.2008.n.060

95.

Yeh, H. C., Maruthur, N. M., Wang, N. Y., Jerome, G. J., Dalcin, A. T., Tseng, E., White, K., Miller, E. R., Juraschek, S. P., Mueller, N. T., Charleston, J., Durkin, N., Hassoon, A., Lansey, D. G., Kanarek, N. F., Carducci, M. A., & Appel, L. J. (2021). Effects of behavioral weight loss and metformin on IGFs in cancer survivors: A randomized trial. Journal of Clinical Endocrinology and Metabolism, 106(10), e4179–e4191. https://doi.org/10.1210/clinem/dgab266

96.

Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016). Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology, 27(12). https://doi.org/10.1093/annonc/mdw410

97.

Ross, K. H., Gogineni, K., Subhedar, P. D., Lin, J. Y., & McCullough, L. E. (2019). Obesity and cancer treatment efficacy: Existing challenges and opportunities. Cancer, 125(10). https://doi.org/10.1002/cncr.31976

98.

Goodwin, P. J., Chen, B. E., Gelmon, K. A., et al. (2022). Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: The MA.32 Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 327(20), 1963–1973. https://doi.org/10.1001/jama.2022.6147CrossRefPubMed

99.

Yamada, S. (2014, April - ). Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Identifier NCT02122185. Retrieved May 2022 from: https://clinicaltrials.gov/show/nct02122185.

100.

Sheng, J. (2022, February 15). Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study (A-NEW). ClinicalTrials.Gov Identifier: NCT04499950.

101.

Seewaldt, V. (2013, July - ). Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer. Identifier NCT01905046. Retrieved May 2022 from: https://Clinicaltrials.Gov/Show/NCT01905046.

102.

Sjöström, L. (2013). Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. Journal of Internal Medicine, 273(3), 219–34. https://doi.org/10.1111/joim.12012

103.

Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., Urman, R. D., Adams, S., Cleek, J. B., Correa, R., Figaro, M. K., Flanders, K., Grams, J., Hurley, D. L., Kothari, S., & Still, C. D. (2019). Clinical Practice Guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update. American College of Endocrinology and the American Association of Clinical Endocrinologists, 25(12), 1346–1359. https://doi.org/10.4158/GL-2019-0406

104.

Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA - Journal of the American Medical Association, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567

105.

Park, C. W., & Torquati, A. (2011). Physiology of weight loss surgery. Surgical Clinics of North America, 91(6), 1149–61. https://doi.org/10.1016/j.suc.2011.08.009

106.

Arterburn, D., Wellman, R., Emiliano, A., Smith, S. R., Odegaard, A. O., Murali, S., Williams, N., Coleman, K. J., Courcoulas, A., Yates Coley, R., Anau, J., Pardee, R., Toh, S., Janning, C., Cook, A., Sturtevant, J., Horgan, C., & McTigue, K. M. (2018). Comparative effectiveness and safety of bariatric procedures for weight loss a PCORnet cohort study. Annals of Internal Medicine, 169(11), 741–750. https://doi.org/10.7326/M17-2786

107.

Li, J. F., Lai, D. D., Lin, Z. H., Jiang, T. Y., Zhang, A. M., & Dai, J. F. (2014). Comparison of the long-term results of Roux-en-Y gastric bypass and sleeve gastrectomy for morbid obesity: A systematic review and meta-analysis of randomized and nonrandomized trials. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 24(1), 1–11. https://doi.org/10.1097/SLE.0000000000000041

108.

Schauer, D. P., Feigelson, H. S., Koebnick, C., Caan, B., Weinmann, S., Leonard, A. C., Powers, J. D., Yenumula, P. R., & Arterburn, D. E. (2019). Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort. Annals of Surgery, 269(1), 95–101. https://doi.org/10.1097/SLA.0000000000002525

109.

Tee, M. C., Cao, Y., Warnock, G. L., Hu, F. B., & Chavarro, J. E. (2013). Effect of bariatric surgery on oncologic outcomes: A systematic review and meta-analysis. Surgical Endoscopy, 27(12), 4449–56. https://doi.org/10.1007/s00464-013-3127-9

110.

Adams, T. D., Stroup, A. M., Gress, R. E., Adams, K. F., Calle, E. E., Smith, S. C., Halverson, R. C., Simper, S. C., Hopkins, P. N., & Hunt, S. C. (2009). Cancer incidence and mortality after gastric bypass surgery. Obesity, 17(4), 796–802. https://doi.org/10.1038/oby.2008.610

111.

Mackenzie, H., Markar, S. R., Askari, A., Faiz, O., Hull, M., Purkayastha, S., Møller, H., & Lagergren, J. (2018). Obesity surgery and risk of cancer. British Journal of Surgery, 105(12), 1650–1657. https://doi.org/10.1002/bjs.10914

112.

Wiggins, T., Antonowicz, S. S., & Markar, S. R. (2019). Cancer Risk Following Bariatric Surgery—Systematic Review and Meta-analysis of National Population-Based Cohort Studies. Obesity Surgery, 29(3), 1031–1039. https://doi.org/10.1007/s11695-018-3501-8

113.

Bailly, L., Fabre, R., Pradier, C., & Iannelli, A. (2020). Colorectal cancer risk following bariatric surgery in a nationwide study of French individuals with obesity. JAMA Surgery, 155(5), 395–402. https://doi.org/10.1001/jamasurg.2020.0089

114.

Aravani, A., Downing, A., Thomas, J. D., Lagergren, J., Morris, E. J. A., & Hull, M. A. (2018). Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. Cancer Epidemiology, 53, 99–104. https://doi.org/10.1016/j.canep.2018.01.002

115.

Tao, W., Konings, P., Hull, M. A., Adami, H. O., Mattsson, F., & Lagergren, J. (2017). Colorectal Cancer Prognosis Following Obesity Surgery in a Population-Based Cohort Study. Obesity Surgery, 27(5), 1233–1239. https://doi.org/10.1007/s11695-016-2431-6

116.

Hussan, H., Stanich, P. P., Gray, D. M., Krishna, S. G., Porter, K., Conwell, D. L., & Clinton, S. K. (2017). Prior Bariatric Surgery Is Linked to Improved Colorectal Cancer Surgery Outcomes and Costs: A Propensity-Matched Analysis. Obesity Surgery, 27(4), 1047–1055. https://doi.org/10.1007/s11695-016-2421-8

117.

Neff, R., Havrilesky, L. J., Chino, J., O’Malley, D. M., & Cohn, D. E. (2015). Bariatric surgery as a means to decrease mortality in women with type i endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome. Gynecologic Oncology, 138(3), 597–602. https://doi.org/10.1016/j.ygyno.2015.07.002

118.

Zhang, S., Ikramuddin, S., Beckwith, H. C., Sheka, A. C., Wirth, K. M., & Blaes, A. H. (2020). The Impact of Bariatric Surgery on Breast Cancer Recurrence: Case Series and Review of Literature. Obesity Surgery, 30(2), 780–785. https://doi.org/10.1007/s11695-019-04099-6

119.

Hadefi, A., Arvanitakis, M., Huberty, V., & Devière, J. (2020). Metabolic endoscopy: Today’s science—tomorrow’s treatment. United European Gastroenterology Journal, 8(6), 685–694. https://doi.org/10.1177/2050640620926837

120.

Ruban, A., Uthayakumar, A., Ashrafian, H., & Teare, J. P. (2018). Endoscopic Interventions in the Treatment of Obesity and Diabetes. Digestive Diseases and Sciences, 63(7), 1694–1705. https://doi.org/10.1007/s10620-018-5117-1

121.

Boyages, J., Kastanias, K., Koelmeyer, L. A., Winch, C. J., Lam, T. C., Sherman, K. A., Munnoch, D. A., Brorson, H., Ngo, Q. D., Heydon-White, A., Magnussen, J. S., & Mackie, H. (2015). Liposuction for Advanced Lymphedema: A Multidisciplinary Approach for Complete Reduction of Arm and Leg Swelling. Annals of Surgical Oncology, 22, S1263–70. https://doi.org/10.1245/s10434-015-4700-3

122.

Benatti, F., Solis, M., Artioli, G., Montag, E., Painelli, V., Saito, F., Baptista, L., Costa, L. A., Neves, R., Seelaender, M., Ferriolli, E., Pfrimer, K., Lima, F., Roschel, H., Gualano, B., & Lancha, A. (2012). Liposuction induces a compensatory increase of visceral fat which is effectively counteracted by physical activity: A randomized trial. Journal of Clinical Endocrinology and Metabolism, 97(7), 2388–95. https://doi.org/10.1210/jc.2012-1012

123.

Weber, R. v., Buckley, M. C., Fried, S. K., & Kral, J. G. (2000). Subcutaneous lipectomy causes a metabolic syndrome in hamsters. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 279(3), R936–43. https://doi.org/10.1152/ajpregu.2000.279.3.r936

124.

Castagneto-Gissey, L., Casella-Mariolo, J., Casella, G., & Mingrone, G. (2020). Obesity Surgery and Cancer: What Are the Unanswered Questions? Frontiers in Endocrinology, 11, 213. https://doi.org/10.3389/fendo.2020.00213

125.

Genser, L., Casella Mariolo, J. R., Castagneto-Gissey, L., Panagiotopoulos, S., & Rubino, F. (2016). Obesity, Type 2 Diabetes, and the Metabolic Syndrome: Pathophysiologic Relationships and Guidelines for Surgical Intervention. Surgical Clinics of North America, 96(4), 681–701. https://doi.org/10.1016/j.suc.2016.03.013

126.

Cani, P. D., & Jordan, B. F. (2018). Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nature Reviews Gastroenterology and Hepatology, 15(11), 671–682. https://doi.org/10.1038/s41575-018-0025-6

Titel: Clinical interventions to break the obesity and cancer link: a narrative review
verfasst von: Nakul J. Bhardwaj
Kacey Chae
Jennifer Y. Sheng
Hsin-Chieh Yeh
Publikationsdatum: 06.08.2022
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2022
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10055-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical interventions to break the obesity and cancer link: a narrative review

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Obesity: a perfect storm for carcinogenesis

Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance

The timing of adiposity and changes in the life course on the risk of cancer

The obesity-breast cancer link: a multidisciplinary perspective

Obesity, cancer risk, and time-restricted eating

Preface

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie